Tamsulosin (Alpha-blocker)
Treatment for Benign Prostatic Hyperplasia
Typical Dosage: 0.4-0.8mg once daily
Effectiveness
65%
Safety Score
72%
Clinical Trials
19
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
0.4-0.8mg once daily
Time to Effect
Within days to 2 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
12(Treat 12 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$250
Side Effect Mgmt:$75
Total Annual:$355
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$546
Tamsulosin (Alpha-blocker) Outcomes
for Benign Prostatic Hyperplasia
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+65%
Common Side Effects
Dizziness
+18%
Abnormal ejaculation (retrograde)
+7%
Rhinitis
+7%
Orthostatic hypotension
+4%
Active Clinical Trials
2 active trials recruiting for Tamsulosin (Alpha-blocker) in Benign Prostatic Hyperplasia
Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction
NCT07815379ACTIVE NOT RECRUITINGPHASE4
140 participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Oct 12, 2025
Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy
NCT06865430RECRUITINGNA
82 participants
INTERVENTIONAL
Ankara, Turkey (Türkiye)
Started: Mar 4, 2025
Completed Clinical Trials
13 completed trials for Tamsulosin (Alpha-blocker) in Benign Prostatic Hyperplasia
Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH
NCT00359905COMPLETEDPHASE3
1.23K participants
INTERVENTIONAL
Sheffield, United Kingdom
Started: May 1, 2006
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
NCT02757768COMPLETEDPHASE4
715 participants
INTERVENTIONAL
Homewood, United States +78 more
Started: Jun 13, 2016
Deprescribing Tamsulosin in Older Men
NCT05415748COMPLETEDPHASE4
31 participants
INTERVENTIONAL
San Francisco, United States
Started: Sep 18, 2021
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
NCT01323998COMPLETED
35K participants
OBSERVATIONAL
Started: Apr 1, 2010
Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia
NCT00399464COMPLETEDPHASE3
1.18K participants
INTERVENTIONAL
Tokyo, Japan
Started: Nov 1, 2006
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
NCT01435954COMPLETED
13.6K participants
OBSERVATIONAL
Started: Aug 1, 2010
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
NCT01332487COMPLETED
4.07K participants
OBSERVATIONAL
Started: Aug 1, 2010
Tadalafil Plus Tamsulosin for Male LUTS and ED
NCT04383093COMPLETED
75 participants
OBSERVATIONAL
Started: Jan 1, 2017
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
NCT01386983COMPLETED
332 participants
OBSERVATIONAL
Started: Mar 1, 2009
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
NCT02656173COMPLETEDPHASE4
568 participants
INTERVENTIONAL
Aichi, Japan +57 more
Started: Jan 25, 2016
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
NCT01332435COMPLETED
6.9K participants
OBSERVATIONAL
Started: Nov 1, 2009
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
NCT01390870COMPLETED
400 participants
OBSERVATIONAL
Started: May 1, 2009
Early Versus Late Catheter Removal in Patients With Acute Urinary Retention Secondary to BPH Under Tamsulosin Treatment
NCT03280420COMPLETEDNA
60 participants
INTERVENTIONAL
Cairo, Egypt
Started: Mar 12, 2017